[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015015523A2 - composição de vacina nasal para influenza - Google Patents

composição de vacina nasal para influenza

Info

Publication number
BR112015015523A2
BR112015015523A2 BR112015015523A BR112015015523A BR112015015523A2 BR 112015015523 A2 BR112015015523 A2 BR 112015015523A2 BR 112015015523 A BR112015015523 A BR 112015015523A BR 112015015523 A BR112015015523 A BR 112015015523A BR 112015015523 A2 BR112015015523 A2 BR 112015015523A2
Authority
BR
Brazil
Prior art keywords
influenza
vaccine composition
nasal vaccine
nasal
adjuvant
Prior art date
Application number
BR112015015523A
Other languages
English (en)
Other versions
BR112015015523B1 (pt
Inventor
Ainai Akira
Hasegawa Hideki
Suzuki Tadaki
Kamishita Taizou
Miyazaki Takashi
Original Assignee
Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Toko Yakuhin Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan As Represented By Director General Of Nat Institute Of Infectious Diseases, Toko Yakuhin Kogyo Kk filed Critical Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
Publication of BR112015015523A2 publication Critical patent/BR112015015523A2/pt
Publication of BR112015015523B1 publication Critical patent/BR112015015523B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "composição de vacina nasal para influenza". a presente invenção refere-se a uma composição de vacina para a influenza para administração por pulverização na mucosa nasal a qual compreende um vírion de influenza total inativado e um material à base de gel compreendendo carbóxi vinil polímero, que é caracterizado por não compreender um adjuvante.
BR112015015523-5A 2012-12-28 2013-10-23 Composição de vacina nasal para influenza BR112015015523B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012287900 2012-12-28
JP2012-287900 2012-12-28
PCT/JP2013/078721 WO2014103488A1 (ja) 2012-12-28 2013-10-23 経鼻インフルエンザワクチン組成物

Publications (2)

Publication Number Publication Date
BR112015015523A2 true BR112015015523A2 (pt) 2017-07-11
BR112015015523B1 BR112015015523B1 (pt) 2023-02-23

Family

ID=51020588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015015523-5A BR112015015523B1 (pt) 2012-12-28 2013-10-23 Composição de vacina nasal para influenza

Country Status (27)

Country Link
US (2) US20160015800A1 (pt)
EP (2) EP3566715A1 (pt)
JP (1) JP6247639B2 (pt)
KR (1) KR102071099B1 (pt)
CN (2) CN104884086A (pt)
AU (1) AU2013367751B2 (pt)
BR (1) BR112015015523B1 (pt)
CA (1) CA2894223C (pt)
CY (1) CY1122372T1 (pt)
DK (1) DK2939692T3 (pt)
ES (1) ES2731899T3 (pt)
HK (1) HK1209646A1 (pt)
HU (1) HUE044434T2 (pt)
IL (1) IL239284B (pt)
LT (1) LT2939692T (pt)
MX (1) MX371154B (pt)
MY (1) MY173503A (pt)
NZ (1) NZ708922A (pt)
PH (1) PH12015501482B1 (pt)
PL (1) PL2939692T3 (pt)
PT (1) PT2939692T (pt)
RU (1) RU2652296C2 (pt)
SG (2) SG11201504648TA (pt)
SI (1) SI2939692T1 (pt)
TR (1) TR201910293T4 (pt)
TW (1) TWI624280B (pt)
WO (1) WO2014103488A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010114169A1 (en) * 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration
US9408880B2 (en) 2013-12-20 2016-08-09 Katherine Rose Kovarik Method and system for prevention and treatment of allergic and inflammatory diseases
US9585920B2 (en) 2011-02-04 2017-03-07 Katherine Rose Kovarik Method and system for treating cancer cachexia
US9457077B2 (en) 2009-11-18 2016-10-04 Katherine Rose Kovarik Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US10314865B2 (en) 2011-02-04 2019-06-11 Katherine Rose Kovarik Method and system for treating cancer and other age-related diseases by extending the healthspan of a human
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
JP6322844B2 (ja) 2014-06-25 2018-05-16 東興薬品工業株式会社 医療用シリンジに用いられる点鼻用噴霧ノズル
AU2015281148B2 (en) * 2014-06-25 2020-07-30 Toko Yakuhin Kogyo Kabushiki Kaisha Influenza vaccine nasal vaccination system
CN105342982B (zh) * 2015-11-19 2018-08-28 上海现代药物制剂工程研究中心有限公司 经鼻给药的流感疫苗免疫制剂及其制备方法
TW201722472A (zh) * 2015-11-27 2017-07-01 Nitto Denko Corp 口腔內投與用疫苗醫藥組合物及口腔內投與用疫苗醫藥組合物之製造方法
KR101944953B1 (ko) * 2016-07-29 2019-02-01 메타볼랩(주) 점막용 항인플루엔자 바이러스 조성물
CA3075423A1 (en) * 2017-10-05 2019-04-11 Toko Yakuhin Kogyo Co., Ltd. Nasal hepatitis b vaccine composition and method for producing same
US20220361741A1 (en) 2019-07-03 2022-11-17 Aillis Inc. Pharmaceutical composition for treating influenza virus infections
CN113117093B (zh) * 2019-12-31 2024-02-09 辽宁成大生物股份有限公司 一种适用于鼻粘膜递送流感疫苗的促进剂
CA3238000A1 (en) 2021-12-02 2023-06-08 Toko Yakuhin Kogyo Co., Ltd. Nasal vaccine-spraying formulation for simultaneously targeting nasal mucosa and nasopharynx
WO2023120535A1 (ja) * 2021-12-20 2023-06-29 東興薬品工業株式会社 ポリアクリル酸系ポリマーを含有するワクチンアジュバント剤およびその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678245B2 (ja) * 1989-07-04 1994-10-05 東興薬品工業株式会社 鼻腔内噴霧投与用インフルエンザワクチンゲル製剤
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
KR20160064249A (ko) * 2005-03-23 2016-06-07 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｃｄ4 ｔ－세포 및/또는 개선된 ｂ－메모리 세포 반응을 유도하는 인플루엔자 바이러스 및 수중유 에멀젼 애주번트의 용도
NZ572066A (en) 2006-04-21 2010-12-24 Toko Yakuhin Kogyo Kk Container that provides airless and predetermined amount of fluid dispensing without unnecessary pumping
ES2642042T3 (es) * 2006-04-21 2017-11-15 Toko Yakuhin Kogyo Kabushiki Kaisha Preparación pulverizable de tipo gel para adhesión a la piel/mucosa, y sistema de administración que usa la preparación
WO2010114169A1 (en) 2009-03-31 2010-10-07 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Method for prophylaxis of influenza using vaccine for intranasal administration

Also Published As

Publication number Publication date
CY1122372T1 (el) 2021-01-27
IL239284B (en) 2020-02-27
CN110038123A (zh) 2019-07-23
TR201910293T4 (tr) 2019-07-22
TWI624280B (zh) 2018-05-21
PH12015501482A1 (en) 2015-09-21
US20190091324A1 (en) 2019-03-28
BR112015015523B1 (pt) 2023-02-23
CA2894223A1 (en) 2014-07-03
EP3566715A1 (en) 2019-11-13
DK2939692T3 (da) 2019-07-08
PT2939692T (pt) 2019-06-27
TW201427724A (zh) 2014-07-16
RU2015130634A (ru) 2017-02-01
US20160015800A1 (en) 2016-01-21
LT2939692T (lt) 2019-08-12
ES2731899T3 (es) 2019-11-19
HK1209646A1 (en) 2016-04-08
RU2652296C2 (ru) 2018-04-25
CA2894223C (en) 2021-04-06
NZ708922A (en) 2019-10-25
SI2939692T1 (sl) 2019-10-30
EP2939692A1 (en) 2015-11-04
KR20150102995A (ko) 2015-09-09
JP6247639B2 (ja) 2017-12-13
MX371154B (es) 2020-01-20
WO2014103488A1 (ja) 2014-07-03
AU2013367751A8 (en) 2015-08-27
IL239284A0 (en) 2015-07-30
AU2013367751B2 (en) 2018-02-08
JPWO2014103488A1 (ja) 2017-01-12
SG11201504648TA (en) 2015-07-30
PH12015501482B1 (en) 2015-09-21
AU2013367751A1 (en) 2015-07-09
PL2939692T3 (pl) 2019-10-31
MY173503A (en) 2020-01-29
MX2015008380A (es) 2016-03-15
EP2939692B1 (en) 2019-04-24
HUE044434T2 (hu) 2019-10-28
CN104884086A (zh) 2015-09-02
SG10201705190TA (en) 2017-07-28
KR102071099B1 (ko) 2020-01-29
EP2939692A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
BR112015015523A2 (pt) composição de vacina nasal para influenza
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
BR112013031268A8 (pt) polipeptídeos
BR112015012197A2 (pt) terapia de combinação
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
CL2018002692A1 (es) Vacuna bivalente contra el virus de gripe porcina.(divisional solicitud 201701961)
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112013020743A2 (pt) composições e métodos para a terapia e diagnóstico de influenza
BR112015012841A2 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112014013878A2 (pt) emplastro
PH12016502529B1 (en) Influenza vaccine nasal vaccination system
BR112014023092A8 (pt) Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
BR112013023354A2 (pt) vacina para rinite equina
BR112017013373A2 (pt) anestésico à base de tetracaína.
CU20120115A7 (es) Composición farmacéutica sólida para administración bucal de agomelatina
BR112022008711A2 (pt) Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
BR112015005968A2 (pt) formas de dosagem orais de liberação prolongada compreendendo partículas derivadas do ácido propiônico com baixo ponto de fusão
BR112022011850A2 (pt) Vacina respiratória oral
UY35294A (es) Composición farmacéutica sólida para administración bucal de agomelatina
CR20110469A (es) Vacuna inactivada del virus del dengue con un adjuvante libre de aluminio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2013, OBSERVADAS AS CONDICOES LEGAIS